Segment, Geographic, and Product Information

12 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Segment, Geographic, and Product Information

Note 8 — Segment, Geographic, and Product Information

The Company's operations include four product lines which constitute one operating segment engaged in providing solutions to improve the health and well-being of people living with diabetes. The Company's CODM is the Chief Executive Officer. The CODM assesses performance and decides how to allocate resources for the Company's one operating segment based on consolidated net income that is reported on the Consolidated Statements of Income. The Company has also evaluated the significant segment expenses incurred by our single segment regularly provided to the CODM. The significant expenses provided to the CODM are consistent with those reported on the Consolidated Statements of Income and include cost of products sold, selling and administrative expense, research and development, other operating expenses, interest expense, other income and expense, and income taxes. The CODM uses these metrics to make key operating decisions which include approving the design of key commercialization strategies, decision about key personnel, and approving annual operating and capital budgets. Our CODM considers budget-to-actual variances and year over year performance when making decisions supporting resource allocation. The Company manages assets on a consolidated basis as reported on the Consolidated Balance Sheets.

Disaggregation of Revenues

The Company has distribution agreements with regional or national distributors (including wholesalers and medical suppliers) to ensure broad availability of its products as well as a direct sales force in certain countries and regions around the world. In the United States and Canada, the Company utilizes its large and small key account managers that call on payers, retailers, wholesalers and institutional customers, and field-based territory managers that call on health care providers and pharmacies. In certain markets within Europe, the Company has dedicated sales representatives and in certain regions of the Middle East and Africa, the Company has distribution agreements. In Asia, the Company has distribution agreements and in China, the Company relies on its own commercial team to support sales execution. In Latin America, the Company maintains distribution agreements and direct sales representatives.

Revenues by geographic region are as follows:

	Year ended September 30,
	2025		2024		2023
United States	$	579.1	$	607.2	$	601.4
International(1)	501.3		515.9		519.4
Total	$	1,080.4	$	1,123.1	$	1,120.8

(1)For the fiscal years ended September 30, 2025, 2024, and 2023 no individual country outside of the United States generated net revenues that represented more than 10.0% of total revenues.

Revenues by product family are as follows:

	Year ended September 30,
	2025		2024		2023
Pen Needles	$	784.1	$	844.4	$	829.2
Syringes	124.6		126.2		138.1
Safety	137.8		129.4		126.3
Other(1)	14.0		10.3		14.2
Contract Manufacturing	19.9		12.8		13.0
Total	$	1,080.4	$	1,123.1	$	1,120.8

(1)Other includes product sales for swabs and other accessories. Other also reflects the recognition of changes in estimates for the Italian payback measure relating to certain prior fiscal years between 2015 and 2023.